Enhanced prophylaxis also associated with improvements in severe disease or death, new TB, cryptococcal or candida infection, and hospitalization in study from sub-Saharan Africa.
Despite lack of impact on all-cause mortality, raltegravir-intensified ART associated with much faster reduction in HIV-1 RNA levels and greater increase in CD4+ cell counts at Week 48.
Similar CD4+ cell count increases, rates of virologic failure, and safety outcomes observed for each regimen.
In this pilot study, 90% of patients maintained virologic suppression through Week 48; 1 patient who had baseline HIV-1 RNA > 100,000 copies/mL experienced protocol-defined virologic failure at Week 36, and 1 patient was a victim of suicide deemed unrelated to study drugs.
Whereas rates of AIDS-defining events, serious outcomes, and death were low and not different for those who stopped vs continued ART, rates of WHO stage 2/3 events were cut in half for women who continued ART in the postpartum period.
Study in low- and middle-income countries included > 60% women, suggests single-tablet RPV/TDF/FTC could provide viable ART alternative for virologically suppressed HIV-infected individuals.
Superiority in ITT analysis driven by fewer discontinuations due to adverse events and virologic nonresponse; no treatment-emergent resistance observed in dolutegravir/abacavir/lamivudine arm
In first randomized interventional evaluation of HIV PrEP in US women, no safety or tolerability differences seen between maraviroc-containing PrEP vs TDF + FTC; no new HIV infections occurred over study course.
Decreased adherence to PrEP over time aligned with increasing intervals between planned clinic visits.
Switch to daily DTG plus RPV associated with improved liver function tests, improved lipid profile, and stable kidney function.